Change in PDL Status for Antivirals, Oral Drug Class Effective March 7, 2024

Effective March 7, 2024, the Texas Health and Human Services Commission (HHSC) has removed the non-preferred status from the generic valganciclovir tablets on the preferred drug list (PDL).

This change is in response to the shortage of the preferred brand name product Valcyte tablets. The preferred status of Valcyte tablets will not change, so that existing stock may be used.

Providers can now prescribe valganciclovir tablets without requiring a PDL prior authorization, which will allow clients continued access to the necessary medication.

The non-preferred status of the following drugs was removed: